Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical course of hospitalized COVID-19 patients treated with remdesivir with or without antibiotics
IRCT20210510051248N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of remdesivir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Erythrocyte sedimentation rate, C-reactive protein and 5 more. Started Jan 2022; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210510051248N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210510051248N1.